Chenodiol
Chenodiol, Ctexli (chenodiol) is a small molecule pharmaceutical. Chenodiol was first approved as Chenix on 1983-07-28. The pharmaceutical is active against bile acid receptor. In addition, it is known to target fMet-Leu-Phe receptor and G-protein coupled bile acid receptor 1.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
No data
Trade Name
FDA
EMA
Chenodiol, Ctexli (discontinued: Chenix)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Chenodiol
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| CTEXLI | Mirum Pharmaceuticals | N-219488 RX | 2025-02-21 | 1 products, RLD, RS |
Show 1 discontinued
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
HCPCS
No data
Clinical
Clinical Trials
37 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Cerebrotendinous xanthomatosis | D019294 | — | — | — | — | 1 | — | — | 1 |
| Xanthomatosis | D014973 | — | — | — | — | 1 | — | — | 1 |
Indications Phases 2
No data
Indications Phases 1
No data
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Chenodiol |
| INN | chenodeoxycholic acid |
| Description | Chenodeoxycholic acid is a dihydroxy-5beta-cholanic acid that is (5beta)-cholan-24-oic acid substituted by hydroxy groups at positions 3 and 7 respectively. It has a role as a human metabolite and a mouse metabolite. It is a bile acid, a dihydroxy-5beta-cholanic acid and a C24-steroid. It is a conjugate acid of a chenodeoxycholate. |
| Classification | Small molecule |
| Drug class | — |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | C[C@H](CCC(=O)O)[C@H]1CC[C@H]2[C@H]3[C@H](CC[C@@]21C)[C@@]1(C)CC[C@@H](O)C[C@H]1C[C@H]3O |
Identifiers
| PDB | — |
| CAS-ID | 474-25-9 |
| RxCUI | — |
| ChEMBL ID | CHEMBL240597 |
| ChEBI ID | 16755 |
| PubChem CID | 10133 |
| DrugBank | DB06777 |
| UNII ID | 0GEI24LG0J (ChemIDplus, GSRS) |
Target
Agency Approved
NR1H4
NR1H4
Organism
Homo sapiens
Gene name
NR1H4
Gene synonyms
BAR, FXR, HRR1, RIP14
NCBI Gene ID
Protein name
bile acid receptor
Protein synonyms
farnesoid X nuclear receptor, Farnesoid X-activated receptor, Farnesol receptor HRR-1, Nuclear receptor subfamily 1 group H member 4, Retinoid X receptor-interacting protein 14, RXR-interacting protein 14
Uniprot ID
Mouse ortholog
Nr1h4 (20186)
bile acid receptor (Q60641)
Variants
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 9,994 documents
View more details
Safety
Black-box Warning
Black-box warning for: Chenodal
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
344 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use